Here are five updates in orthobiologics and regenerative medicine to know from the first quarter of 2023:
1. The world's first viable bone matrix that provides lineage-committed bone cells, LifeNet Health's ViviGen MIS, is now available for use in trauma procedures.
2. Apex Biologix has chosen Jim Rogers to be the company's next CEO.
3. Orthobiologics company DiscGenics shared data supporting its IDCT (rebonuputemcel) allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease.
4. A three-year study of Creative Medical Technology Holdings' StemSpine procedure found it was effective for addressing chronic lower back pain.
5. Orthobiologics company Royal Biologics has commercially launched a new platelet-rich plasma system, Bioincyte. Bioincyte converts traditional platelet-rich plasma to platelet-rich fibrin matrix, eliminating extensive contamination of red and white blood cells. Bioincyte converts the PRP through a controlled process that protects and preserves platelets.